| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Net sales | 27,253 | 23,238 | 17,639 | |
| Cost of sales | 12,134 | 10,735 | 8,668 | |
| Gross profit | 15,119 | 12,503 | 8,971 | |
| Research and development | 8,195 | 8,873 | 7,590 | |
| Sales and marketing | 16,045 | 15,623 | 13,402 | |
| General and administrative | 7,922 | 7,879 | 6,621 | |
| Total operating expenses | 32,162 | 32,375 | 27,613 | |
| Loss from operations | -17,043 | -19,872 | -18,642 | |
| Interest income | 2,833 | 3,005 | 2,436 | |
| Other income (expense), net | 1 | -2 | - | |
| Change in fair value of warrant liabilities | 0 | 0 | 12,450 | |
| Total other income (expense), net | 2,834 | 3,003 | -10,014 | |
| Net loss | -14,209 | -16,869 | -28,656 | |
| Unrealized gain (loss) on short-term investments | 205 | -91 | 175 | |
| Comprehensive loss | -14,004 | -16,960 | -28,481 | |
| Earnings per share, basic | -0.33 | -0.39 | -0.93 | |
| Earnings per share, diluted | -0.33 | -0.39 | -0.93 | |
| Weighted average number of shares outstanding, basic | 43,634,006 | 43,390,652 | 30,714,769 | |
| Weighted average number of shares outstanding, diluted | 43,634,006 | 43,390,652 | 30,714,769 | |
Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. (BBNX)